Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2017 - 2026)

Takeda Pharmaceutical's Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $170.9 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 25.82% year-over-year to $170.9 million; the TTM figure through Mar 2026 stood at $170.9 million (down 25.82% YoY), while the FY2026 annual figure was $178.1 million, down 22.84% from the prior year.
• Non-Current Deferred Tax Liability was $170.9 million for Q1 2026 at Takeda Pharmaceutical, down from $203.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.9 billion in Q1 2022 to a low of $170.9 million in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $1.3 billion across 5 years, with a median of $767.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability sank 81.87% in 2024, then fell 17.97% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.8 billion in 2022, then slumped by 67.29% to $900.0 million in 2023, then sank by 72.47% to $247.8 million in 2024, then retreated by 17.97% to $203.3 million in 2025, then declined by 15.92% to $170.9 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $170.9 million (Q1 2026), $203.3 million (Q4 2025), and $224.2 million (Q3 2025), per Business Quant data.